PriceTargets.com logo

60 Degrees Pharmaceuticals - SXTP Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $2.40
  • Forecasted Upside: 908.40%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.24 As of 04/29/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for SXTP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 60 Degrees Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SXTP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SXTP

Analyst Price Target is $2.40
▲ +908.40% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for 60 Degrees Pharmaceuticals in the last 3 months. The average price target is $2.40, with a high forecast of $2.40 and a low forecast of $2.40. The average price target represents a 908.40% upside from the last price of $0.24.

This chart shows the closing price for SXTP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 contributing investment analysts is to moderate buy stock in 60 Degrees Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/6/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2024HC WainwrightReiterated RatingNeutralLow
10/20/2023HC WainwrightReiterated RatingNeutralLow
10/2/2023Ascendiant Capital MarketsInitiated CoverageBuy$2.40Low
(Data available from 4/30/2019 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
60 Degrees Pharmaceuticals logo
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.
Read More

Today's Range

Now: $0.24
Low: $0.23
High: $0.24

50 Day Range

MA: $0.27
Low: $0.23
High: $0.31

52 Week Range

Now: $0.24
Low: $0.22
High: $8.65

Volume

21,934 shs

Average Volume

286,921 shs

Market Capitalization

$2.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 60 Degrees Pharmaceuticals?

The following sell-side analysts have issued reports on 60 Degrees Pharmaceuticals in the last year: Ascendiant Capital Markets, and HC Wainwright.
View the latest analyst ratings for SXTP.

What is the current price target for 60 Degrees Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for 60 Degrees Pharmaceuticals in the last year. Their average twelve-month price target is $2.40, suggesting a possible upside of 908.4%. Ascendiant Capital Markets has the highest price target set, predicting SXTP will reach $2.40 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $2.40 for 60 Degrees Pharmaceuticals in the next year.
View the latest price targets for SXTP.

What is the current consensus analyst rating for 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SXTP.

What other companies compete with 60 Degrees Pharmaceuticals?

Other companies that are similar to 60 Degrees Pharmaceuticals include Allarity Therapeutics, Clever Leaves, Avenue Therapeutics, Biophytis and NovaBay Pharmaceuticals. Learn More about companies similar to 60 Degrees Pharmaceuticals.

How do I contact 60 Degrees Pharmaceuticals' investor relations team?

60 Degrees Pharmaceuticals' physical mailing address is 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036, United States. The company's listed phone number is 202-327-5422 and its investor relations email address is [email protected]. The official website for 60 Degrees Pharmaceuticals is 60degreespharma.com. Learn More about contacing 60 Degrees Pharmaceuticals investor relations.